T. Rowe Price Associates’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
|
|||||
|
2023
Q4 | $621M | Sell |
|
|||||
|
2023
Q3 | $462M | Buy |
|
|||||
|
2023
Q2 | $577M | Buy |
|
|||||
|
2023
Q1 | $451M | Buy |
|
|||||
|
2022
Q4 | $464M | Buy |
|
|||||
|
2022
Q3 | $498M | Buy |
|
|||||
|
2022
Q2 | $256M | Sell |
|
|||||
|
2022
Q1 | $268M | Buy |
|
|||||
|
2021
Q4 | $256M | Buy |
|
|||||
|
2021
Q3 | $225M | Buy |
|
|||||
|
2021
Q2 | $203M | Buy |
|
|||||
|
2021
Q1 | $203M | Buy |
|
|||||
|
2020
Q4 | $145M | Buy |
|
|||||
|
2020
Q3 | $106M | Buy |
|
|||||
|
2020
Q2 | $152M | Sell |
|
|||||
|
2020
Q1 | $131M | Buy |
|
|||||
|
2019
Q4 | $55.1M | Buy |
|
|||||
|
2019
Q3 | $7.47M | Buy |
|
|||||
|
2019
Q2 | $9.08M | Buy |
|